These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28039477)

  • 1. Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.
    Zhao J; Liu S; Gao D; Ding S; Niu Z; Zhang H; Huang Z; Qiu J; Li Q; Li N; Xie F; Cui J; Lu J
    Oncotarget; 2017 Feb; 8(6):9935-9946. PubMed ID: 28039477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.
    Zhao R; Huang Y; Cheng G; Liu J; Shao P; Qin C; Hua L; Yin C
    PLoS One; 2014; 9(9):e106933. PubMed ID: 25268808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.
    Boesen L; Thomsen FB; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thomsen HS; Jakobsen H
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):609-616. PubMed ID: 30988407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
    Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
    PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.